Daniel E. Geffken - Jul 7, 2022 Form 3 Insider Report for ProMIS Neurosciences Inc. (PMN)

Role
Chief Financial Officer
Signature
/s/ Jason L. Langford, Attorney-in-Fact for Daniel E. Geffken
Stock symbol
PMN
Transactions as of
Jul 7, 2022
Transactions value $
$0
Form type
3
Date filed
7/7/2022, 07:28 PM
Previous filing
Jun 9, 2022
Next filing
May 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PMN Common Shares 5.85K Jul 7, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PMN Option (right to buy) Jul 7, 2022 Common Shares 8.33K $10.80 Direct F1, F2
holding PMN Option (right to buy) Jul 7, 2022 Common Shares 8.33K $10.80 Direct F1, F3
holding PMN Warrants (right to buy) Jul 7, 2022 Common Shares 1.04K $18.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Conversion or exercise price is in Canadian dollars.
F2 The option agreement provides that 20% of the options vested immediately, with the balance vesting ratably over 36 months. The option was granted on March 1, 2017.
F3 The option agreement provides that the options become exercisable in twelve equal monthly installments beginning one month after the grant. The option was granted on November 12, 2021.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney